Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - vincristine sulfate 2mg;  ;  ;   - injection with diluent - 2 mg - active: vincristine sulfate 2mg       excipient: lactose monohydrate benzyl alcohol sodium chloride water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - vincristine sulfate 5mg;  ;  ;   - injection with diluent - 5 mg - active: vincristine sulfate 5mg       excipient: lactose monohydrate benzyl alcohol sodium chloride water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - vincristine sulfate - solution for injection - 1mg, 5mg (douglas) - active: vincristine sulfate

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 1mg - solution for injection - 1 mg - active: vincristine sulfate 1mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - vincristine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml excipient: acetic acid methyl hydroxybenzoate propyl hydroxybenzoate sodium acetate trihydrate water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - vincristine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml excipient: mannitol water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 2mg - solution for injection - 2 mg - active: vincristine sulfate 2mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 5mg - solution for injection - 5 mg - active: vincristine sulfate 5mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: sulfuric acid; water for injections; mannitol; sodium hydroxide - vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: 1. leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukemia and blastic crisis of chronic myelogenous leukaemia. 2. malignant lymphomas, including hodgkin's disease and non-hodgkin's lymphomas. 3. multiple myeloma. 4. solid tumors, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas. 5. paediatirc solid tumors, including ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, wilm's tumour, retinoblastoma and medulloblastoma. 6. idiopathic thrombocytytopenic pupura.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - vincristine sulphate is indicated alone or in combination with other antitumor therapies for the treatment of the following conditions: 1. leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia 2. malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas 3. multiple myeloma 4. solid tumours, including breast carcinoma, microcellular bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas 5. paediatric solid tumours, including ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, wilms' tumour, retinoblastoma and medulloblastoma 6. idiopathic thrombocytopenic purpura. patients with true itp refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. if patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses